US Pharmaceuticals & Biotechnology "*INVITE & SLIDES* GLP1 impact on the..."

Research evidence excerpt

US Pharmaceuticals & Biotechnology "*INVITE & SLIDES* GLP1 impact on the..."

Global Research

18 May 2026ab

US Pharmaceuticals & Biotechnology Equities

Americas*INVITE & SLIDES* GLP1 impact on the fitness

consumer sector Pharmaceuticals

Michael Yee

Analyst

michael.yee@ubs.com

UBS is hosting their first-ever Virtual Fitness Day today on May 19th, with 6 +1-305-536 9101

public and private companies in the space covered by Arpiné Kocharyan. We will also be

Arpine Kocharyan

hosting a panel to discuss the GLP1 landscape and its impact on the consumer sector as

it relates to fitness at 3pm ET. You can register HERE. arpine.kocharyan@ubs.com

+1-212-713 2086

There are a lot of encouraging data points suggesting the fitness sector could Dina Elmonshed

benefit from GLP1s -- regardless of significant weight loss -- as GLP1s have Analyst

increased efficacy when combined with exercise. Exercise complements GLP1 dina.elmonshed@ubs.com

therapy through additional fat reduction and improved cardiorespiratory fitness versus +1-212-649 8276

GLP1 therapies alone. Adding exercise to GLP1s supports weight maintenance as well, Kyle Yang, CFA

which should reduce the weight rebound that often occurs after patients get off the Associate Analyst

drug. kyle.yang@ubs.com

+1-212-713 1458

We have updated our sector slides - see inside - to run through some of the literature on Matthew Hagood

GLP1 and fitness too. We make no changes to our global GLP1 model or estimates. Associate Analyst

matthew.hagood@ubs.com

+1-212-713 1107

Hosts: Madeleine Lee

Associate Analyst

Arpiné Kocharyan, UBS Leisure, Gaming & Lodging Analyst madeleine.lee@ubs.com

+1-212-713 1476

Agenda: Roy Zawadzki, PhD

8:30am-8:55am ET — Opening Remarks: Emma Lovewell – Peloton Instructor, Best roy.zawadzki@ubs.com